Therapeutic synergy emerges from combined GPX4 inhibitor and PARP inhibitor treatment, which cooperatively induce ferroptosis in BRCA1-deficient ovarian cancer cells and potently inhibit tumor growth. Here, BRCA1 is linked to neoplasm.